JNJ

227.58

+1.12%↑

UNH

366.5

+3.49%↑

TMO

470.15

+0.34%↑

ISRG

466.67

-0.89%↓

ABT

93.81

+1.03%↑

JNJ

227.58

+1.12%↑

UNH

366.5

+3.49%↑

TMO

470.15

+0.34%↑

ISRG

466.67

-0.89%↓

ABT

93.81

+1.03%↑

JNJ

227.58

+1.12%↑

UNH

366.5

+3.49%↑

TMO

470.15

+0.34%↑

ISRG

466.67

-0.89%↓

ABT

93.81

+1.03%↑

JNJ

227.58

+1.12%↑

UNH

366.5

+3.49%↑

TMO

470.15

+0.34%↑

ISRG

466.67

-0.89%↓

ABT

93.81

+1.03%↑

JNJ

227.58

+1.12%↑

UNH

366.5

+3.49%↑

TMO

470.15

+0.34%↑

ISRG

466.67

-0.89%↓

ABT

93.81

+1.03%↑

Search

Heron Therapeutics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

1.21 2.54

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1.19

Max

1.24

Pagrindiniai rodikliai

By Trading Economics

Pajamos

15M

-3M

Pardavimai

2.4M

41M

Pelnas, tenkantis vienai akcijai

-0.02

Pelno marža

-7.278

Darbuotojai

128

EBITDA

13M

-792K

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+278.15% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-05-11

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

6.2M

224M

Ankstesnė atidarymo kaina

-1.33

Ankstesnė uždarymo kaina

1.21

Naujienos nuotaikos

By Acuity

50%

50%

177 / 348 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bearish Evidence

Heron Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-28 23:33; UTC

Karštos akcijos

Stocks to Watch: Robinhood, Visa, Seagate Technology, NXP Semiconductors

2026-04-28 23:24; UTC

Uždarbis

Visa 2Q Revenue Climbs as Consumers Keep Spending; Board Authorizes $20 Billion Buyback -- Update

2026-04-28 23:15; UTC

Svarbiausios naujienos

U.K. Economy to Suffer Large Loss of Output, Higher Inflation as Result of Middle East Conflict

2026-04-28 22:46; UTC

Uždarbis

Booking Holdings Cuts Outlook as Middle East Conflict Weighs on Travel Demand -- Update

2026-04-28 22:37; UTC

Uždarbis

Prudential PLC 1Q New Business Profit $686.0 Million, Up 10% on Year

2026-04-28 22:15; UTC

Uždarbis
Svarbiausios naujienos

Mondelez Reports Developing Market Growth Offsetting U.S., Europe Weakness -- Update

2026-04-28 23:33; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Gold Edges Lower on Prospects of Dollar Strength -- Market Talk

2026-04-28 23:31; UTC

Uždarbis

China Petroleum & Chemical 1Q Net Rose on Higher Crude Oil Prices >0386.HK

2026-04-28 23:31; UTC

Uždarbis

China Petroleum & Chemical 1Q Capex Was CNY25.17B >0386.HK

2026-04-28 23:30; UTC

Uždarbis

China Petroleum & Chemical 1Q Net CNY17.74B Vs. Net CNY13.98B >0386.HK

2026-04-28 23:30; UTC

Uždarbis

China Petroleum & Chemical 1Q Rev CNY706.70B Vs. CNY735.36B >0386.HK

2026-04-28 23:19; UTC

Rinkos pokalbiai
Uždarbis

Visa Points to Spending Boost from Tax Refunds in U.S. -- Market Talk

2026-04-28 23:09; UTC

Uždarbis

Visa 2Q Revenue Climbs as Consumers Keep Spending; Board Authorizes $20B Buyback -- Update

2026-04-28 23:03; UTC

Rinkos pokalbiai

Australia's Inflation Outlook Looks Pretty Grim -- Market Talk

2026-04-28 23:01; UTC

Svarbiausios naujienos

NIESR Sees One Rate Rise to 4% in Benign Scenario

2026-04-28 23:01; UTC

Svarbiausios naujienos

NIESR Sees U.K. Economy Growing by Just 0.5% in 'Adverse' Middle East Scenario

2026-04-28 23:01; UTC

Svarbiausios naujienos

NIESR: BOE's Key Rate Should Rise to 5.25% in Adverse Scenario

2026-04-28 23:01; UTC

Svarbiausios naujienos

U.K.'s NIESR Lowers 2026 U.K. Economic Growth Forecast to 0.9% From 1.4% in 'Benign' Scenario

2026-04-28 23:01; UTC

Svarbiausios naujienos

NIESR Sees Inflation Peaking at Over 6% in Adverse Scenario

2026-04-28 22:51; UTC

Uždarbis

Robinhood Earnings Fall Short. A Crypto Slump Is the Culprit. -- Barrons.com

2026-04-28 22:48; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-04-28 22:48; UTC

Rinkos pokalbiai

Australia's 1Q CPI Will Likely Provide Little Relief For RBA -- Market Talk

2026-04-28 22:40; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Australian 1Q CPI Will Likely Keep May Hike Alive -- Market Talk

2026-04-28 22:32; UTC

Uždarbis

Booking Beats on Profit. Travel Demand Outlook Clouded By Iran War. -- Barrons.com

2026-04-28 22:25; UTC

Įsigijimai, susijungimai, perėmimai

Pernod Ricard and Brown-Forman End Deal Talks -- Update

2026-04-28 22:22; UTC

Uždarbis

Prudential PLC 1Q New Business Profit $686.0M, Up 10% on Year

2026-04-28 22:17; UTC

Rinkos pokalbiai

Canada Fiscal Update Puts Central Bank on Track to Raise Rates -- Market Talk

2026-04-28 22:14; UTC

Uždarbis

Prudential PLC 1Q APE Sales Up 6% on Year, to $1.823B >2378.HK

2026-04-28 22:14; UTC

Uždarbis

Prudential PLC 1Q New Business Profit $686.0M, Up 10% on Year >2378.HK

2026-04-28 22:07; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Canada Chamber Frets Over Lost Fiscal Room -- Market Talk

Akcijų palyginimas

Kainos pokytis

Heron Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

278.15% į viršų

12 mėnesių prognozė

Vidutinis 4.5 USD  278.15%

Aukščiausias 6 USD

Žemiausias 3 USD

Remiantis 2 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Heron Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

2 ratings

2

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

2.0001 / 2.42Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Bearish Evidence

Vidutinės trukmės periodas

Bullish Evidence

Ilgalaikis periodas

Bullish Evidence

Rinkos nuotaikos

By Acuity

177 / 348 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Heron Therapeutics Inc

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.
help-icon Live chat